Consequently, different anti-VEGF therapies have been developed to treat neovascularization, in particular in AMD and diabetic retinopathy.3 However, anti-VEGF drugs require repeat injections to maintain stable and long-term treatment efficacy. This evidence concerns the gene VEGFA and age-related macular degeneration.